7:45 am Check In & Coffee

8:30 am Chair’s Opening Remarks

• Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge

Enhancing Clinical Success Through Rigorous Donor Characterization & Strategic Implementation

8:45 am Keynote Panel Discussion: Exploring Innovations & Challenges in Donor Selection for Allogeneic Therapies

• Stacey Cranert Senior Director ImmunoOncology, Poseida Therapeutics
• Heather Pariseau Munoz Director - Apheresis Operations, Sana Biotechnology
• Akshata Ijantkar Analytical Lead for BMS Cell Therapy Products, Bristol Myers Squibb
• Colleen Delaney Founder & Chief Scientific Officer, Executive Vice President - Research & Development, Deverra Therapeutics

9:30 am Identification of Healthy Donor Phenotypic & Functional Signatures That Predict Allogeneic, Hypoimmune CAR-T Cell Potency

• Darin Salloum Director, Sana Biotechnology

10:00 am Morning Refreshments & Speed Networking

Enhancing Clinical Success Through Rigorous Donor Characterization & Strategic Implementation

11:00 am Deep Characterization of HSC-derived Natural Killer Cells Reveals Features of Optimal Donors

• Stefanie Maurer Senior Scientist, ImmuneBridge

Accelerating Market Access Through Robust Donor Screening, Apheresis & Viral Testing Protocols

11:30 am Navigating Donor Variability for More Consistent & High-Quality Allogeneic Cell Therapies

• Stacey Cranert Senior Director ImmunoOncology, Poseida Therapeutics

12:00 pm Lunch & Networking

1:00 pm Optimizing the Apheresis Process, Best Practices in Donor Recruitment & Viral Testing

• Heather Pariseau Munoz Director - Apheresis Operations, Sana Biotechnology

1:30 pm Roundtable with: Blood Centers of America

2:00 pm Afternoon Refreshments & Poster Session

The Fundamental Role of Diverse Donor Pools & Implementing Robust Systems for Traceability of Medical Products

3:00 pm Key Elements of Traceability for Medical Products of Human Origin

• Karen Moniz Technical Director, ICCBBA

3:30 pm The Critical Role of a Diverse Donor Pool in Allogeneic Therapies

• Colleen Delaney Founder & Chief Scientific Officer, Executive Vice President - Research & Development, Deverra Therapeutics

4:00 pm Chair’s Closing Remarks

• Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge

4:15 pm End of Day One